Briumvi® (ublituximab-xiiy)
for Multiple Sclerosis
Briumvi (ublituximab-xiiy) is used to treat relapsing forms of multiple sclerosis (MS) in adults, including clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive disease. It works by targeting and destroying B cells, which are involved in the immune response. Briumvi binds to the CD20 protein on B cells' surfaces, reducing their activity and lessening the immune system's impact on the nervous system, which drives MS symptoms. Briumvi is a CD20 monoclonal antibody.
